JP2007510405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510405A5 JP2007510405A5 JP2006536073A JP2006536073A JP2007510405A5 JP 2007510405 A5 JP2007510405 A5 JP 2007510405A5 JP 2006536073 A JP2006536073 A JP 2006536073A JP 2006536073 A JP2006536073 A JP 2006536073A JP 2007510405 A5 JP2007510405 A5 JP 2007510405A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- nucleic acid
- group
- molecule according
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000033616 DNA repair Effects 0.000 claims 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 125000003636 chemical group Chemical group 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 3
- 231100000518 lethal Toxicity 0.000 claims 3
- 230000001665 lethal effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 230000007018 DNA scission Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 claims 2
- 150000004713 phosphodiesters Chemical group 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 1
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 claims 1
- 229930024421 Adenine Natural products 0.000 claims 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- 230000004543 DNA replication Effects 0.000 claims 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 108060002716 Exonuclease Proteins 0.000 claims 1
- 102000015335 Ku Autoantigen Human genes 0.000 claims 1
- 108010025026 Ku Autoantigen Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000013165 exonuclease Human genes 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 230000002601 intratumoral effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 1
- -1 morpholino nucleic acid Chemical class 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 229940113082 thymine Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03292666A EP1526177A1 (en) | 2003-10-24 | 2003-10-24 | Nucleic acids useful for triggering tumor cell lethality |
| EP03292666.9 | 2003-10-24 | ||
| PCT/EP2004/012857 WO2005040378A1 (en) | 2003-10-24 | 2004-10-25 | Nucleic acids useful for triggering tumor cell lethality |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011027662A Division JP5662822B2 (ja) | 2003-10-24 | 2011-02-10 | 腫瘍細胞致死性をトリガーするのに有用な核酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007510405A JP2007510405A (ja) | 2007-04-26 |
| JP2007510405A5 true JP2007510405A5 (https=) | 2007-12-06 |
| JP4743789B2 JP4743789B2 (ja) | 2011-08-10 |
Family
ID=34384721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536073A Expired - Lifetime JP4743789B2 (ja) | 2003-10-24 | 2004-10-25 | 腫瘍細胞致死性をトリガーするのに有用な核酸 |
| JP2011027662A Expired - Lifetime JP5662822B2 (ja) | 2003-10-24 | 2011-02-10 | 腫瘍細胞致死性をトリガーするのに有用な核酸 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011027662A Expired - Lifetime JP5662822B2 (ja) | 2003-10-24 | 2011-02-10 | 腫瘍細胞致死性をトリガーするのに有用な核酸 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7595302B2 (https=) |
| EP (2) | EP1526177A1 (https=) |
| JP (2) | JP4743789B2 (https=) |
| CN (1) | CN1871350B (https=) |
| AT (1) | ATE485375T1 (https=) |
| AU (1) | AU2004284228B2 (https=) |
| CA (1) | CA2542942C (https=) |
| CY (1) | CY1111060T1 (https=) |
| DE (1) | DE602004029699D1 (https=) |
| DK (1) | DK1675954T3 (https=) |
| ES (1) | ES2354359T3 (https=) |
| PL (1) | PL1675954T3 (https=) |
| PT (1) | PT1675954E (https=) |
| SI (1) | SI1675954T1 (https=) |
| WO (1) | WO2005040378A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7476729B2 (en) * | 2003-10-24 | 2009-01-13 | Institut Curie | Dbait and uses thereof |
| EP1944369A1 (en) * | 2007-01-12 | 2008-07-16 | The Centre National de la Recherche Scientifique | Dbait and its standalone uses thereof |
| WO2009149921A2 (en) * | 2008-06-11 | 2009-12-17 | Bionucleon S.R.L. | Inhibition of hrp-3 using modified oligonucleotides |
| US9205099B2 (en) | 2010-06-22 | 2015-12-08 | Dna Therapeutics | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| AU2015202211B2 (en) * | 2010-06-22 | 2016-09-01 | Centre National De La Recherche Scientifique | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
| AU2014316676B2 (en) * | 2013-09-04 | 2020-07-23 | Csir | Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression |
| EP3919621A1 (en) * | 2014-06-23 | 2021-12-08 | The General Hospital Corporation | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| US10821128B2 (en) * | 2016-03-01 | 2020-11-03 | Onxeo | Treatment of cancer by systemic administration of Dbait molecules |
| WO2017186882A1 (en) | 2016-04-29 | 2017-11-02 | Onxeo | A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules |
| US10876116B2 (en) | 2016-07-15 | 2020-12-29 | The Board Of Regents Of The University Of Oklahoma | Anti-ARID3a treatments for inflammatory disorders |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| CN108261548B (zh) * | 2018-01-10 | 2020-04-10 | 浙江大学 | 一种纳米复合物及其制备方法和应用 |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| CA3097044A1 (en) | 2018-04-17 | 2019-10-24 | The General Hospital Corporation | Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents |
| WO2020127965A1 (en) | 2018-12-21 | 2020-06-25 | Onxeo | New conjugated nucleic acid molecules and their uses |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
| AR122644A1 (es) | 2020-06-19 | 2022-09-28 | Onxeo | Nuevas moléculas de ácido nucleico conjugado y sus usos |
| JP2025500922A (ja) | 2021-12-16 | 2025-01-15 | ヴァレリオ・セラピューティクス | 新規のコンジュゲートされた核酸分子及びその使用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ255028A (en) * | 1992-07-02 | 1997-03-24 | Hybridon Inc | Antisense oligonucleotides resistant to nucleolytic degradation |
| US6441158B1 (en) * | 1997-12-31 | 2002-08-27 | Medical College Of Georgia Research Institute, Inc. | Oligomers that bind to ku protein |
| EP0978561A1 (en) * | 1998-08-07 | 2000-02-09 | Hoechst Marion Roussel Deutschland GmbH | Antisense oligonucleotides for the inhibition of VEGF expression |
| AU2002241952A1 (en) * | 2001-01-22 | 2002-07-30 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
| CA2476468A1 (en) | 2002-02-13 | 2003-08-21 | Medbridge, Inc. | Protein carrier system for therapeutic oligonucleotides |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
-
2003
- 2003-10-24 EP EP03292666A patent/EP1526177A1/en not_active Withdrawn
-
2004
- 2004-10-25 CA CA2542942A patent/CA2542942C/en not_active Expired - Lifetime
- 2004-10-25 PT PT04817274T patent/PT1675954E/pt unknown
- 2004-10-25 ES ES04817274T patent/ES2354359T3/es not_active Expired - Lifetime
- 2004-10-25 DK DK04817274.6T patent/DK1675954T3/da active
- 2004-10-25 AU AU2004284228A patent/AU2004284228B2/en not_active Expired
- 2004-10-25 US US10/576,818 patent/US7595302B2/en not_active Expired - Lifetime
- 2004-10-25 PL PL04817274T patent/PL1675954T3/pl unknown
- 2004-10-25 CN CN200480031278.XA patent/CN1871350B/zh not_active Expired - Lifetime
- 2004-10-25 WO PCT/EP2004/012857 patent/WO2005040378A1/en not_active Ceased
- 2004-10-25 AT AT04817274T patent/ATE485375T1/de active
- 2004-10-25 DE DE602004029699T patent/DE602004029699D1/de not_active Expired - Lifetime
- 2004-10-25 EP EP04817274A patent/EP1675954B1/en not_active Expired - Lifetime
- 2004-10-25 JP JP2006536073A patent/JP4743789B2/ja not_active Expired - Lifetime
- 2004-10-25 SI SI200431547T patent/SI1675954T1/sl unknown
-
2010
- 2010-12-23 CY CY20101101190T patent/CY1111060T1/el unknown
-
2011
- 2011-02-10 JP JP2011027662A patent/JP5662822B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007510405A5 (https=) | ||
| JP2010515707A5 (https=) | ||
| TWI784934B (zh) | 抑制lpa之基因表現之組合物及方法 | |
| JP6977998B2 (ja) | アンチセンス核酸 | |
| ES2242291T3 (es) | Nucleotidos bi y triciclicos, analogos de nucleotidos y oligonucleotidos. | |
| US20190062740A1 (en) | COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS | |
| JP3143475B2 (ja) | 二本鎖ｄｎａの核酸類似体による誘導転写 | |
| TW201639962A (zh) | Ｒｎａ干擾劑 | |
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| CN108350454A (zh) | 等位基因选择性基因编辑及其用途 | |
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JP2016530882A5 (https=) | ||
| US11261440B2 (en) | Antisense oligonucleic acid | |
| JP2016502858A5 (https=) | ||
| JP2008531018A5 (https=) | ||
| CN108064313A (zh) | 用于抑制因子xii的基因表达的组合物和方法 | |
| KR20180098528A (ko) | 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝 | |
| EP1526177A1 (en) | Nucleic acids useful for triggering tumor cell lethality | |
| JP5559159B2 (ja) | 修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害 | |
| ES2865446T3 (es) | Marcadores diagnósticos para el tratamiento de trastornos proliferativos celulares con inhibidores de la telomerasa | |
| US10183977B2 (en) | Stabilized STAT3 decoy oligonucleotides and uses therefor | |
| US20160251652A1 (en) | Compositions for inhibiting checkpoint gene expression and uses thereof | |
| CN112513062B (zh) | 含有寡聚核苷酸的小细胞肺癌治疗药 | |
| JP2007533742A5 (ja) | 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 | |
| JP2021515784A5 (https=) |